AMD1

Across TCGA pan-cancer cohorts, AMD1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AMD1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AMD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AMD1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where AMD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	1.000	0.509	.013	12	view →
LUAD	OS	Median	II,III,IV	1.000	0.691	.013	11	view →
LSCC	DFS	Median	III,IV	0.988	0.540	.027	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AMD1–HNSC (OS)

Open the HNSC breakdown →